On May 27, 2026, Boston Scientific BSX experienced a significant decline of approximately 10%, reaching a 52-week low as the company reported a slowdown in demand for its WATCHMAN cardiac implant. In its upcoming Q1 2026 earnings release, Boston Scientific has revised its full-year organic net sales growth forecast to between 6.5% and 8.0%, citing challenges with WATCHMAN volumes in the U.S. and its electrophysiology sector.
- Market Cap: $77.47 billion
- GF Scoreā¢: 83/100, indicating strong long-term performance potential
- Insider Activity: There were 3 insider buying transactions over the past 3 months, totaling 9,800 shares purchased.
What's Behind the News?
The recent decline in Boston Scientific's stock price is primarily attributed to a slowdown in demand for its WATCHMAN cardiac implant, a critical product in the company's portfolio. This decline has raised concerns among investors, leading to a significant drop in the stock price. The company has also revised its full-year organic net sales growth forecast, which adds to the uncertainty surrounding its near-term performance. Despite these challenges, Boston Scientific remains optimistic about its future and plans to continue investing in its business to drive growth.
Boston Scientific Corp is a developer, manufacturer, and marketer of less invasive medical devices. The company operates within the healthcare sector, specifically in the Medical Devices & Instruments industry. With a market capitalization of approximately $77.47 billion, Boston Scientific produces devices for various medical applications, including angioplasty, cardiac rhythm management, and interventional oncology. Notably, foreign sales account for roughly 36% of the firm's total sales, highlighting its global reach.
How Is BSX Valued?
Currently, GF Valueā¢ data is not available for Boston Scientific. However, the stock's P/E ratio stands at 21.81x, which is close to its 5-year low of 22.04. This suggests that the stock may be undervalued relative to its historical performance. Investors may want to consider this valuation context as they assess the stock's potential. For more details, visit the BSX stock page.
What Does BSX's GF Scoreā¢ Tell Us?
The GF Scoreā¢ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Scoreā¢ values have been found to generate higher long-term returns (backtested 2006-2021).
| Metric | Rating |
|---|---|
| GF Scoreā¢ | 83 |
| Financial Strength | 6/10 |
| Profitability | 9/10 |
| Growth | 10/10 |
Boston Scientific's strengths lie in its robust growth potential, as indicated by its perfect growth rank of 10/10. Additionally, the company demonstrates strong profitability with a rank of 9/10. However, its financial strength is rated at 6/10, suggesting that while the company is stable, there may be areas for improvement. For further insights, visit the BSX stock page.
What Are Insiders Doing with BSX Stock?
In the past three months, there have been three insider buying transactions, with a total of 9,800 shares purchased. This insider activity may indicate confidence in the company's future prospects, despite the recent challenges faced by Boston Scientific.
What This Means for Investors
While Boston Scientific is currently facing challenges with its WATCHMAN product and has revised its growth forecast, the company's strong GF Scoreā¢ of 83/100 and insider buying activity suggest that there may be potential for recovery and growth in the long term. Investors should weigh these factors carefully as they consider their positions in the stock. For the complete analysis, visit the BSX stock page. You can also use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions
What is BSX's GF Scoreā¢?
BSX's GF Scoreā¢ is 83/100, indicating strong long-term performance potential based on various financial metrics.
How is BSX valued?
BSX has a P/E ratio of 21.81x, which is close to its 5-year low of 22.04, suggesting it may be undervalued relative to its historical performance.
What is BSX's P/E ratio compared to historical?
BSX's current P/E ratio of 21.81x is close to its 5-year low of 22.04, indicating that the stock may be trading at a lower valuation compared to its historical averages.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
